Navigation Links
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
Date:12/16/2013

JERUSALEM, Dec. 16, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML). The early results show that BL-8040, as a stand-alone therapy and in combination with high-dose Cytarabine (Ara-C), is safe at all doses tested to date, and triggers substantial mobilization of cancer cells from the bone marrow to the peripheral blood, thereby increasing the vulnerability of the cells to chemotherapy treatment. In addition, signs of robust apoptosis (cell death) of cancer cells were observed following administration of the higher doses tested to date. The study has not yet reached the highest planned doses, suggesting that a strengthening of BL-8040's effects may be observed in future dosing cohorts.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769 )

The Phase 2 trial is a multicenter, open-label study under an IND, and is designed to evaluate the safety and efficacy of repeated escalating doses of BL-8040 in adult patients with relapsed or refractory AML. The primary endpoints of the study are to assess the safety and tolerability of BL-8040. Secondary endpoints include the pharmacokinetic profile of the drug and an efficacy evaluation, indicated by the extent of mobilization of cancer cells from the bone marrow to the peripheral blood, the level of cancer cell death (apoptosis) and clinical responses.

Eight patients have already been enrolled in the study, out of a total expected enrollment of up to 50 patients at eight clinical sites in the U.S. and Isr
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
4. BioLineRx Reports Third Quarter 2013 Financial Results
5. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
6. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
7. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
11. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive ... regulatory and marketplace changes. CI leaders who adjust will ... In a new Best Practices, LLC study CI ... actionable insights, including: - Use secondary research ... primary research - Internal staff who are ...
(Date:8/29/2014)... 2014   Mast Therapeutics, Inc. (NYSE ... that Santosh Vetticaden, Chief Medical Officer and Senior ... personal reasons, in mid-September.  Edwin L. Parsley ... Pharmaceuticals, which Mast acquired earlier this year, will ... interim Chief Medical Officer.  Dr. Parsley previously was ...
(Date:8/29/2014)... 2014 Research and Markets has ... Industry Report, 2014-2017" report to their offering. ... proportion of reimbursement for medical expenses, the Chinese orthopedic ... scale presenting a CAGR of 19.2% during 2009-2013. Trauma ... segments of orthopedic instruments in China ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... Asante Solutions, Inc. (Asante), a medical device company focused ... mark for its Pearl Insulin Pump, the only insulin ... mark is a European proof of conformity that certifies ... Asante has begun discussions with potential distribution partners in ...
... Neuralstem, Inc. (NYSE Amex: CUR ) announced ... Phase I safety trial of Neuralstem,s human spinal cord ... Lou Gehrig,s disease), and unpaid Neuralstem consultant, presented interim ... reported yesterday at the American Academy of Neurology (AAN ...
Cached Medicine Technology:Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump 2Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 2Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 3Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 4
(Date:8/30/2014)... "My niece developed a nighttime fever, and I ... fever might get worse," said an inventor from Montgomery, ... how she was doing, I developed this monitoring system." ... a child's temperature. The unit instantly alerts parents if ... medical care can be given, which is designed to ...
(Date:8/30/2014)... York (PRWEB) August 30, 2014 Bringing ... Profit By Search announces the Labor Day discount ... clients will surely get the complete services related to ... SEO professionals, Content Writers, and others do have a ... perfection that reflects in their work and since the ...
(Date:8/30/2014)... "I had a handicapped friend who could not walk ... from Wetumpka, Ala. "In order to help her be able ... came up with a way for her to use her ... the patent-pending Deezers to allow crutches to be used on ... walkers, or canes at the beach. The device reduces the ...
(Date:8/30/2014)... Bethesda, MD (PRWEB) August 30, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) robs people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 One of the ... era is the gluten-free diet. Originally meant for sufferers of ... a catchall for people who are looking to get healthier ... not only is this kind of information erroneous, it also ... problems because of a drastic change in their food ...
Breaking Medicine News(10 mins):Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2
... 21 As the pace of global,competition ... research,groups to keep up. Effective market research ... customers, markets and competitors as,reference points to ... from benchmarking leader Best Practices, LLC., ...
... got easier and a lot more accessible to the public ... a ground-breaking partnership between a young British entrepreneur, a global ... , Debuted April 20 to offer individuals a meaningful way ... hope www.MalariaEngage.org will do for African research what ...
... Don,t eat for 2, because complications increase with excess weight, ... been considered a kind of gastronomical free-for-all. After all, ... food she eats, right? , The problem is, the ... and extra weight gain can increase the risk of pregnancy ...
... J. Deitsch, Chairman,and Chief Executive Officer of Nutra ... will be updating the investment,community through his personal ... dynamic profile will include exclusive interviews with,Rik J. ... his personal,stock watchlist, photos of company products and ...
... Sales force performance,significantly impacts growth and ... to effectively disseminate vital information to their ... to the overall success of,their companies., ... Excellence:,Resources, Structure and Processes to Optimize Pharmaceutical ...
... point to the brain-draining effects of decision-making , , FRIDAY, April ... flavors of ice cream, people,s lives are full of choices. ... sap your stamina, your ability to stay focused and even ... people faced with a variety of choices had more trouble ...
Cached Medicine News:Health News:Creating an Effective Market Research Group to Generate High-Impact Business Results 2Health News:International health experts to enlist the public in war on African malaria 2Health News:International health experts to enlist the public in war on African malaria 3Health News:International health experts to enlist the public in war on African malaria 4Health News:International health experts to enlist the public in war on African malaria 5Health News:International health experts to enlist the public in war on African malaria 6Health News:International health experts to enlist the public in war on African malaria 7Health News:International health experts to enlist the public in war on African malaria 8Health News:Extra Pounds During and Between Pregnancies Can Pose Problems 2Health News:Extra Pounds During and Between Pregnancies Can Pose Problems 3Health News:Rik Deitsch, CEO of Nutra Pharma Creates Personal Wall on WallSt.net's Financial Social Community, my.wallst.net 2Health News:Complementary Excerpt Available from Best Practices: Resources, Structure and Processes to Optimize Pharmaceutical Sales Communications 2Health News:Choices Sap Your Stamina, Self Control: Study 2Health News:Choices Sap Your Stamina, Self Control: Study 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: